Ashurst advises Bubs Australia on distribution joint venture for China label infant formula
30 September 2022
Binding agreements have been entered into by Bubs and subsidiaries of Heilongjiang Ubeite Dairy Group Co., Ltd to secure an existing SAMR approved goat infant formula brand slot for Bubs' new ultra-premium range of Bubs® China label formula products.
Bubs will enter into a joint venture agreement with Zhitong (Hangzhou) Health Technology Co., Ltd to distribute China label products in China. Bubs and Zhikang (Hangzhou) Health Technology Co., Ltd will also enter into a manufacturing and distribution agreement for these products, subject to SAMR registration being obtained.
Bubs Founder and CEO, Kristy Carr noted this was an "important milestone for the Company to renew an existing registered SAMR brand slot for Bubs® China label goat infant formula products in partnership with a reputable Chinese infant formula manufacturer."
Partner Kylie Lane commented: "Ashurst is very pleased to have assisted Bubs to reach this milestone with respect to securing SAMR registration of its China label infant formula products."
The Ashurst team was led by counsel Eliza Blandford and partner Kylie Lane, with assistance from: associate Alicia Un (Corporate Transactions, Melbourne); Partner Stuart D'Aloisio (IP/Media); and partner Michael Sheng, senior associate Derek Wang and associate Hetty Li (Corporate Transactions, Shanghai).
